China Health Technology Group Reports FY2025 Revenue of RMB 90.2 Million and Profit of RMB 22.7 Million

Reuters
Sep 30
<a href="https://laohu8.com/S/CHHE">China Health</a> Technology Group Reports FY2025 Revenue of RMB 90.2 Million and Profit of RMB 22.7 Million

For the year ended 30 June 2025, China Health Technology Group Holding Company Limited reported revenue of RMB 90.215 million, compared to RMB 47.606 million for the year ended 30 June 2024. Cost of sales was RMB 82.002 million, up from RMB 45.709 million in the previous year. Gross profit increased to RMB 8.213 million from RMB 1.897 million. Other income amounted to RMB 0.328 million, compared to RMB 0.016 million in the prior year. Other gains, net, were RMB 34.528 million, up from RMB 22.205 million. There was no gain on debt restructuring in 2025, compared to RMB 202.024 million in 2024. Selling and distribution expenses were RMB 0.862 million, down from RMB 1.421 million. Administrative expenses totalled RMB 15.678 million, compared to RMB 21.472 million in the previous year. Revenue by product for 2025: - Sales of timber related products: RMB 36.633 million (2024: RMB 32.521 million) - Sales of ginseng related products: RMB 39.467 million (2024: RMB 15.085 million) - Sales of health products: RMB 14.115 million (2024: nil) Total segment assets as at 30 June 2025 were RMB 196.960 million, compared to RMB 168.605 million as at 30 June 2024. Consolidated total assets amounted to RMB 205.417 million, up from RMB 178.166 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Health Technology Group Holding Co. Ltd. published the original content used to generate this news brief on September 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10